Cohort profile: pediatric patients with Crohn’s disease qualified to biologic therapy
Journal Title: Postępy Nauk Medycznych - Year 2014, Vol 27, Issue 3
Abstract
Introduction. Treatment with modern therapies is an economic problem in every country. Therefore, there are therapeutic programs of National Health Fund (NHF) in Poland which enable to apply such expensive treatment. Currently, Polish NHF programs include biologic therapy with infliximab (IFX) for pediatric patients aged 6-18 years with severe Crohn’s disease (CD).Aim. The aim of this study was to describe the clinical profile of pediatric patients hospitalized in the Department of Gastroenterology, Hepatology and Feeding Disorders, Children’s Memorial Health Institute in Warsaw, who have been qualified to biologic therapy with either infliximab (IFX) or adalimumab (ADA).Material and methods. We have performed a retrospective analysis of 107 children age 13.0 ± 9.3 years diagnosed with CD and treated with IFX and/or ADA within the period of 8 year; time between 2005 and 2013. The data on patient’s demographics, including age, sex, and age at disease onset as well as on the course and behavior of CD have been collected.Results. One hundred and seven CD patients (M: 54, F: 53) aged 13.0 ± 9.3 years were analyzed. Eighty one children (75.7%) received IFX, 26 (24.3%) ADA, and 8 (7.5%) were treated with both agents. Mean disease duration was 5.5 ± 0.83 years. The most frequently found location of lesions was L3 (56.1%). Extraintestinal manifestations were reported in 18 patients (16.8%), and arthralgia/arthritis was the most frequently found condition among them (77.8%). The most frequently found complication were nutritional and growth disorders, observed in 10 patients (9.3%). Mean PCDAI score at qualification was (median± ) 52.5]±27.5. Mean SES-SD (median [interquartile range]) score at qualification was 1 (1.0-22.0).Conclusions. Pediatric patients qualified to biologic therapy have rather severe than moderate course of disease with high PCDAI score.
Authors and Affiliations
Edyta Szymańska, Maciej Dądalski, Grzegorz Oracz, Jarosław Kierkuś
Keywords
Related Articles
- EP ID EP54923
- DOI -
- Views 159
- Downloads 0
Leczenie tętniaków trzewnych i nerkowych metodami wewnątrznaczyniowymi
<b>Wstęp.</b> Tętniaki tętnic trzewnych i nerkowych, mimo że są rzadką patologią naczyniową (częstość występowania w populacji tętniaków trzewnych 0,1-2%, nerkowych 0,01-0,09%), stanowią poważ...
Epidemiologia i diagnostyka mikrobiologiczna inwazyjnej choroby grzybiczej
Inwazyjna choroba grzybicza (ang. invasive fungal disease – IFD) jest zakażeniem narządowym o etiologii grzybiczej rozwijającym się zazwyczaj u pacjentów w stanie immunosupresji. Najczęstszymi postaciami mikrobiologiczny...
Primary hepatobiliary involvement in Hodgkin’s disease – a case report
Hodgkin’s lymphoma is usually a lymph node-based disease. Liver involvement is an unfavorable prognostic factor, as it generally occurs in late stage of this disease. We present a case of 48-year old patient, in whom Hod...
PRINCIPLES FOR RENAL REPLACEMENT THERAPY IN ACUTE KIDNEY INJURY
Despite a substantial technical progress in renal replacement therapy and intensive care medicine the mortality rate for severe acute kidney injury (AKI) remains very high. Moreover there is a lot of controversy in almos...
Genetyka kliniczna czerniaka
Czerniak złośliwy jest jednym z najbardziej agresywnych nowotworów, jego częstość wzrasta gwałtownie w ostatnich latach. Zwiększone ryzyko zachorowania na czerniaka u potomstwa osób chorych na ten nowotwór jak również ro...